316 results about "Catabolism" patented technology

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

A method for isolating succinic acid producing bacteria is provided comprising increasing the biomass of an organism which lacks the ability to catabolize pyruvate, and then subjecting the biomass to glucose-rich medium in an anaerobic environment to enable pyruvate-catabolizing mutants to grow.The invention also provides for a mutant that produces high amounts of succinic acid, which has been derived from a parent which lacked the genes for pyruvate formate lyase and lactate dehydrogenase, and which belongs to the E.coli Group of Bacteria.

The present invention relates to a kit and an intervenously administrable preparation, both, with a signal transmitter precursor, an enhancer of precursor uptake, and an inhibitor of neurotransmitter reuptake or signal transmitter catabolism. The kit also contains an appropriate swab for obtaining oral cells suitable for allelic analysis. The intervenous formulation contains similar materials and, in some cases, ethanol. Either the kit composition or the intervenous formulation may be used as guided by a subjects allelic analysis. Collections of particular alleles, especially those relating to neural system are comprehensible in terms of likelihood of success in the administration of an interveinous formulation or ingestion of components of the subject kit.

The present invention is directed to methods and systems for the treatment of inborn genetic errors or other defects that cause deficiencies of active enzymes or proteins within the cells of the central nervous system. Such methods and systems generally comprise an implantable catheter system designed for the chronic delivery of specially formulated proteins to intrathecal, intracerebroventricular, and/or intraparenchymal regions of the central nervous system. The invention has application in the neuropathic aspects of the broad category of lysosomal storage diseases. These genetic based diseases are the result of insufficient enzyme activity to catabolize specific substances, which thereby accumulate in the cellular lysosomes.

Synthetic Stem Cell-like Tissue Healing and Regeneration Medication with Anti-inflammatory, Protein Synthesis, Enzyme Deficiency Activation and Genetic Therapy, and Anti-cancer Agent derived from a series of inventions that include these products of Biomolecular Engineering, Drug Discovery from a Biologic Periodic Table of Applied Biochemistry and Biophysics. Tissue has a self healing effect promoting tissue healing and tissue regeneration. Not only does it maintain good health but also it has been observed that the patient's blood is withdrawn from the patient and applied to the ulcer has healing qualities. Cartilage placed in a wound promotes and accelerates wound healing. The anabolic biochemical and biophysical equivalent of tissue has been found in these embodiments to have the same pharmacologic qualities, when devoid of genetic DNA mismatch and other catabolic factors including the catabolic effects of microorganism overgrowth that lacks pro-biotic qualities. The healing efficacy of these tissue components gives us further appreciation of the protective action of human tissue over and above and other than the immune protective system or perhaps an integral component part of the immune system.

Methods of determining rate of biosynthesis or breakdown of biological molecules from metabolic derivatives and catabolic products are disclosed herein. In particular, methods of measuring the rates of biosynthesis and breakdown of biological molecules inaccessible or not easily accessible to direct sampling by sampling metabolic derivatives and catabolic products in accessible biological samples are disclosed herein.

This invention provides: 1) a method of treating a subject suffering from a muscle wasting disorder; 2) a method of preventing a muscle wasting disorder in a subject; 3) a method of treating, preventing, suppressing, inhibiting or reducing muscle loss in a subject suffering from a muscle wasting disorder; 4) a method of treating, preventing, inhibiting, reducing or suppressing muscle wasting in a subject suffering from a muscle wasting disorder; and/or 5) a method of treating, preventing, inhibiting, reducing or suppressing muscle protein catabolism in a subject suffering from a muscle wasting disorder, by administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide or any combination thereof, as described herein.

The invention relates to a new pharmacotherapeutical strategy, to an anti-stress, anti-impairment and anti-aging drug and to a process for its manufacturing. The drug has an etio-pathogenic and homeostatic action, was preclinically tested and clinically checked up in geriatric, neurologic, psychiatric and stress-dependent pathology. The drug achieves a synergistic biological, neurometabolic and cell-trophic composition, being elaborated by the association of the following active principles: a) against oxidative and catabolic stress; methionine with aminoethanol phenoxyacetates and/or aminoethyl phenoxyacetamides; b) against anabolic stress; hydroxopyrimidine carboxylates and/or oxopyrrolidine acetamides with potassium, zinc and lithium; c) vasodilative and normolipidemic; nicotinic, alcohol and/or acid, or its derivatives, with magnesium and iodine; d) energo-active and e) anti-toxic; aspartate; fructose; vitamin B1; vitamin B6; monoacid phosphate and sulfate. The process for manufacturing the drug stipulates; a) pharmaceutical preparation in two complementary types of capsules or coated tablets, gastrosoluble and enterosoluble, the last being enteric coated; b) prolonged-release of vasodilator from the enterosoluble unit.

The invention relates to the field of soil remediation and discloses an in-situ bioremediation preparation for heavy metal contaminated soil. The preparation contains fungi and/or bacteria with heavy metal degrading abilities, the fungi refer to at least one of aspergillus niger, rhizomucor variabilis and grey cunninghamella, and the bacteria refer to at least one of bacillus amyloliquefaciens, bacillus licheniformis and bacillus simplex. By using the preparation for in-situ bioremediation of the heavy metal contaminated soil, the problems that the soil needs to move by using a moving method and secondary chemical agent pollution of the cultivated land is easily caused by using a decomposition method can be overcome, at the same time, residual heavy metals in the soil obtained after catabolism through the fungi and/or bacteria can also be fully used, the problem that high residual heavy metals in the soil seriously endanger food safety is solved, the soil micro-ecology is improved, the cultivated ability of soil is more quickly recovered, and the method is relatively low in cost and has broad application prospects.

Methods for treating and preventing the onset and maintainance of multiple drug resistance (MDR) in animals undergoing chemotherapy for cancer are provided. According to the methods, target cells are depleted of adenosine 5'-monophosphate (AMP) and adenosine 5'-triphosphate (ATP) such that the cells are unable to support P-glycoprotein activity. According to one method, a population of target cells is obtained from a host and assayed for loss of methylthioadenosine phosphorylase (MTAse) activity. MTAse catabolizes methylthioadenosine to adenine for endogenous salvage incorporation into the intracellular AMP pool. MTAse deficient cells are treated with a purine synthesis inhibitor, such as L-alanosine, which starves the cells of adenine and suppresses P-glycoprotein activity. MTAse competent cells are also treated for MDR with purine synthesis inhibitors. In conjunction with treatment according to the invention, MTAse competent and deficient cells are also treated for malignancy with other anti-cancer drugs. A method for protecting non-malignant cells from adenine starvation during treatment of malignant cells according to the invention is provided.

The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

Nutrient compositions and methods that sustain and promote positive metabolic energy levels in a targeted manner are disclosed. Methods utilize endogenous energy stores (fat oxidation), increase use of those stores (increasing transport rate), increase available energy (increasing the ability to perform ADP to ATP phosphorylation,) as well as decrease catabolism and increase protein synthesis. Compositions are also disclosed, and include Mono- or Dicreatine-HMB salt; Putrescine Dihydrochloride; Alanine; L-Glutamine, which may be combined with Alanine in a 1:2 to 2:1 molecular ratio; Trimethylglycine; and Guanidinopropionic Acid.

The invention discloses Chinese herbal medicinal weight-reducing tea. The weight-reducing tea is prepared from the following Chinese herbal medicinal raw materials: 4 to 10g of hawthorn, 4 to 10g of cassia seed, 2 to 8g of lotus leaves, 3 to 5g of processed polygonum multiflorum, 1 to 3g of white chrysanthemum, 4 to 10g of lily, 3 to 5g of dried tangerine peel, 2 to 4g of mulberry leaves, and 2 to 4g of rose flowers. The weight-reducing tea can be effectively absorbed by a human body when being drunk in a brewing way, and realizes that over much fat in the body can be subjected to catabiosis in time by promoting fat catabolism, and cannot cause diarrhea; and the weight does not bounce after the weight-reducing tea is used, residual fat is prevented from storing in the body, and the weight is maintained in a certain healthy range. The Chinese herbal medicinal weight-reducing tea has certain beautifying effect.

The present invention relates to compositions for the modulation of inflammation in connective tissues in humans and animals and the modulation of markers of such inflammation, including COX-2, TNF-α, IL-1β, iNOS, p38, and chemokines, comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothioneine, methylsulfanylmethane, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

The invention discloses a brewing method of blueberry enzyme. The method comprises the following steps: sorting blueberry fruit raw materials, crushing and adjusting the pH value; carrying out enzymolysis on blueberry fruit pulp; carrying out low-temperature micro-aerobic yeast fermentation, and preliminarily decomposing macromolecular substances; carrying out low-temperature acetic acid bacterium fermentation to remove ethanol generated in yeast fermentation, and further carrying out catabolism on the wild blueberry fruit pulp; and then carrying out low-temperature compound lactic acid bacterium fermentation, carrying out low-temperature chelation, carrying out pressure filtration for juicing, finally carrying out filtration sterilization, bottling and packing. According to the brewing method disclosed by the invention, multi-layer beneficial microbes are used for fermenting and decomposing wild blueberries, and finally blueberry anthocyanin (VMA) is biologically converted into water-soluble oligomeric proanthocyanidin (OPC), thereby improving the bioactivity and utilization ratio of wild blueberry anthocyanin; and meanwhile, multiple beneficial active substances, namely active proteins, active amino acids and active polypeptides, are produced. The blueberry enzyme obtained by the method disclosed by the invention has the characteristics of full-bodied fruit flavor, crimson color, and dense, slightly sour and palatable taste.